Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays

Vladimir Tichelaar; Helma de Jong; Hendrik Nijland; Hanneke Kluin-Nelemans; Karina Meijer; André Mulder

doi:10.1160/TH11-04-0277

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(05): 990-992
DOI: 10.1160/TH11-04-0277

Letters to the Editor

Schattauer GmbH

Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays

Authors

Vladimir Tichelaar

¹Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Centre Groningen, Groningen, the Netherlands
Helma de Jong

²Department of Laboratory Medicine, University Medical Centre Groningen, Groningen, the Netherlands
Hendrik Nijland

²Department of Laboratory Medicine, University Medical Centre Groningen, Groningen, the Netherlands
Hanneke Kluin-Nelemans

¹Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Centre Groningen, Groningen, the Netherlands
Karina Meijer

¹Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Centre Groningen, Groningen, the Netherlands
André Mulder

²Department of Laboratory Medicine, University Medical Centre Groningen, Groningen, the Netherlands

Abstract

PDF Download

PDF (78 kb)

References

References
1 Eriksson BI, Quinlan DJ. Oral anticoagulants in development- Focus on thromboprophylaxis in patients undergoing orthopedic surgery. Drugs 2006; 66: 1411-1429.
2 Mueck W, Borris LC, Dahl OE. et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
3 Laux V, Perzborn E, Heitmeier S. et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thromb Haemost 2009; 102: 892-899.
4 Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
5 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
6 Samama MM, Martinoli JL, LeFlem L. et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
7 Jiang J, Hu Y, Zhang J. et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects. Thromb Haemost 2010; 103: 234-241.
8 Merriman E, Kaplan Z, Butler J. et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011; 105: 385-386.
9 Mani H, Hesse C, Stratmann G. et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 156-164.
10 The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
11 Hillarp A, Baghaei F, Fagerberg Blixter I. et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
12 O'Donnell J, Tuddenham EG, Manning R. et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-828.
13 Berger M, Mattheisen M, Kulle B. et al. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood 2005; 105: 638-644.
14 O'Donnell J, Mumford AD, Manning RA. et al. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-13.
15 Kamphuisen PW, Eikenboom JC, Vos HL. et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-683.
16 Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost 2010; 8: 621-626.